Class information for:
Level 1: SURROGATE ENDPOINT//PRENTICE CRITERION//PRENTICE CRITERIA

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
17553 530 29.0 72%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
970 10197 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//STATISTICS IN MEDICINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SURROGATE ENDPOINT Author keyword 21 36% 9% 47
2 PRENTICE CRITERION Author keyword 14 100% 1% 7
3 PRENTICE CRITERIA Author keyword 12 86% 1% 6
4 SURROGATE ENDPOINTS Author keyword 10 29% 5% 28
5 LIKELIHOOD REDUCTION FACTOR Author keyword 9 83% 1% 5
6 POST PROGRESSION SURVIVAL Author keyword 9 67% 2% 8
7 META ANALYTIC APPROACH Author keyword 6 80% 1% 4
8 BIOMETR 5 Address 5 47% 2% 8
9 SURROGATE OUTCOME Author keyword 4 42% 2% 8
10 ENDPOINT ADJUDICATION Author keyword 4 75% 1% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 SURROGATE ENDPOINT 21 36% 9% 47 Search SURROGATE+ENDPOINT Search SURROGATE+ENDPOINT
2 PRENTICE CRITERION 14 100% 1% 7 Search PRENTICE+CRITERION Search PRENTICE+CRITERION
3 PRENTICE CRITERIA 12 86% 1% 6 Search PRENTICE+CRITERIA Search PRENTICE+CRITERIA
4 SURROGATE ENDPOINTS 10 29% 5% 28 Search SURROGATE+ENDPOINTS Search SURROGATE+ENDPOINTS
5 LIKELIHOOD REDUCTION FACTOR 9 83% 1% 5 Search LIKELIHOOD+REDUCTION+FACTOR Search LIKELIHOOD+REDUCTION+FACTOR
6 POST PROGRESSION SURVIVAL 9 67% 2% 8 Search POST+PROGRESSION+SURVIVAL Search POST+PROGRESSION+SURVIVAL
7 META ANALYTIC APPROACH 6 80% 1% 4 Search META+ANALYTIC+APPROACH Search META+ANALYTIC+APPROACH
8 SURROGATE OUTCOME 4 42% 2% 8 Search SURROGATE+OUTCOME Search SURROGATE+OUTCOME
9 ENDPOINT ADJUDICATION 4 75% 1% 3 Search ENDPOINT+ADJUDICATION Search ENDPOINT+ADJUDICATION
10 TRUE ENDPOINT 4 75% 1% 3 Search TRUE+ENDPOINT Search TRUE+ENDPOINT

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EVENTS COMMITTEE 7 64% 1% 7
2 CLINICAL EVENTS COMMITTEE 7 67% 1% 6
3 INFARCTION END POINTS 6 50% 2% 8
4 ENDPOINTS 5 24% 4% 19
5 18 RANDOMIZED TRIALS 4 30% 2% 10
6 MARKER EVALUATION 3 100% 1% 3
7 MISMEASURED OUTCOMES 3 100% 1% 3
8 HIERARCHICAL LEVELS 3 50% 1% 4
9 OBJECTIVE RESPONSE 3 50% 1% 4
10 ADJUVANT COLON CANCER 2 67% 0% 2

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Accelerated Approval of Oncology Products: The Food and Drug Administration Experience 2011 50 3 67%
A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer 2012 11 14 86%
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology 2012 14 48 60%
Outcomes and endpoints in trials of cancer treatment: the past, present, and future 2015 4 95 22%
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature 2010 59 40 40%
Biomarkers and surrogate end points-the challenge of statistical validation 2010 80 56 30%
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials 2010 52 26 38%
The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses 2015 1 78 53%
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis 2013 3 10 100%
Statistical evaluation of biomarkers as surrogate endpoints: a literature review 2006 69 58 53%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 BIOMETR 5 5 47% 1.5% 8
2 ONCOL THER Y AREA 4 75% 0.6% 3
3 DATA CANC CLIN TRIALS 3 60% 0.6% 3
4 BIOSTAT QUAL LIFE UNIT EA4184 1 100% 0.4% 2
5 METHODOL QUAL LIFE UNIT ONCOL EA3181 1 100% 0.4% 2
6 BIOSTAT E0338 1 50% 0.2% 1
7 BRANCH BIOMETR 1 50% 0.2% 1
8 CDER OTS OB DBV 1 50% 0.2% 1
9 DECIS SUPPORT UNIT 1 50% 0.2% 1
10 DIGEST ONCOL GASTROENTEROL 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000218969 RECIST//RECIST 11//TUMOR MEASUREMENT
2 0.0000138712 INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION
3 0.0000119299 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//TARGETED MAXIMUM LIKELIHOOD ESTIMATION
4 0.0000098348 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
5 0.0000081925 WORST RANK SCORES//REPRODUCIBILITY PROBABILITY//BOUNDED OUTCOME SCORES
6 0.0000071575 ADAPTIVE TREATMENT STRATEGIES//DYNAMIC TREATMENT REGIME//DYNAMIC TREATMENT REGIMES
7 0.0000069487 RESPONSE SELECTIVE SAMPLING//CASE COHORT DESIGN//OUTCOME DEPENDENT SAMPLING
8 0.0000068503 CONDITIONAL POWER//INTERIM ANALYSIS//SAMPLE SIZE RE ESTIMATION
9 0.0000063325 INTERVAL CENSORING//CURRENT STATUS DATA//INTERVAL CENSORED DATA
10 0.0000060736 DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS